Table 1 Baseline characteristics of the study population by origin, n = 726
From: Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study
Baseline Characteristics | Norwegian-born | Foreign-born | Total | p-value |
|---|---|---|---|---|
Number of individuals | 131 (100) | 595 (100) | 726 (100) | Â |
Gender | Â | Â | Â | 0.115 |
 Male | 69 (53) | 358 (60) | 427 (59) |  |
Age at notification |  |  |  | > 0.001 |
 < 5 years | 37 (28) | 25 (4) | 62 (9) |  |
 5–14 years | 10 (8) | 132 (22) | 142 (20) |  |
 15–34 years | 33 (25) | 315 (53) | 348 (48) |  |
 35–64 years | 36 (27) | 115 (19) | 151 (21) |  |
 > 65 years | 15 (11) | 8 (1) | 23 (3) |  |
Risk groupsa | ||||
Any risk factora | 121(92) | 342 (58) | 463 (64) | Â |
Recent exposure, contacts | 68 (52) | 95 (16) | 163 (22) | > 0.001 |
 Contacts < 5 years | 35 (27) | 3 (0.5) | 38 (5) |  |
Positive chest X-ray, any | 7 (5) | 60 (10) | 67 (9) | 0.090 |
 Fibrotic lesions | 2 (2) | 17 (3) | 19 (3) | 0.388 |
Immunosuppressive condition | 51 (39) | 72 (12) | 123 (17) | > 0.001 |
 HIV infection | – | 12 (2) | 12 (2) |  |
 Chronic renal disease | 1 (1) | 4 (1) | 5 (1) |  |
 Diabetes, any | 1 (1) | 4 (1) | 5 (1) |  |
 Underlying disease relevant for Immunosuppressive treatmentb | 13 (10) | 10 (2) | 23 (3) |  |
 Other medical conditionsc | 36 (7) | 42 (7) | 78 (15) |  |
Interferon Gamma Release Assay (IGRA) |  |  |  | > 0.001 |
 Positive | 94 (72) | 577 (97) | 671 (92) |  |
 Negative | 15 (11) | 5 (1) | 20 (3) |  |
 Inconclusive | 2 (2) | – | 2 (0) |  |
 Missing or unknown | 20 (15) | 13 (2) | 33 (5) |  |
Regimen |  |  |  | > 0.001 |
 3RH dailyI | 97 (74) | 302 (51) | 399 (55) |  |
 3RPH weeklyII | 30 (23) | 276 (46) | 306 (42) |  |
 4R or 6H monotherapy dailyIII | 3 (2) | 15 (3) | 18 (2) |  |
 OtherIV | – | 2 (0) | 2 (0) |  |
 Missing | 1 (1) | – | 1 (0) |  |
TB IR (per 100,000) in country of birth# | ||||
 < 150 | na | 267 (45) | 267 (45) |  |
 150–200 | na | 127 (21) | 127 (21) |  |
 > 200 | na | 197 (33) | 197 (33) |  |
 Missing | na | 4 (1) | 4 (1) |  |